Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $8.58 USD
Change Today +0.19 / 2.26%
Volume 944.3K
INO On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

inovio pharmaceuticals inc (INO) Snapshot

Open
$8.33
Previous Close
$8.39
Day High
$8.64
Day Low
$8.28
52 Week High
07/23/14 - $14.20
52 Week Low
02/24/15 - $6.33
Market Cap
616.1M
Average Volume 10 Days
1.1M
EPS TTM
$-0.60
Shares Outstanding
71.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INOVIO PHARMACEUTICALS INC (INO)

inovio pharmaceuticals inc (INO) Related Businessweek News

No Related Businessweek News Found

inovio pharmaceuticals inc (INO) Details

Inovio Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases. The company’s SynCon immunotherapy design has the ability to break the immune system’s tolerance of cancerous cells; and SynCon product design is also intended to facilitate cross-strain protection against known, as well as new unmatched strains of pathogens, such as influenza. It has completed, current or planned clinical programs of its proprietary SynCon immunotherapies for HPV-caused pre-cancers and cancers, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus, hepatitis B virus, HIV, influenza, and Ebola. Inovio Pharmaceuticals, Inc. has collaborative development agreement with GeneOne Life Sciences to co-develop an Ebola vaccine through phase I clinical trials. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

106 Employees
Last Reported Date: 03/16/15
Founded in 1979

inovio pharmaceuticals inc (INO) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $964.7K
Chief Financial Officer
Total Annual Compensation: $475.4K
Chief Operating Officer
Total Annual Compensation: $486.8K
Chief Medical Officer
Total Annual Compensation: $491.1K
Compensation as of Fiscal Year 2014.

inovio pharmaceuticals inc (INO) Key Developments

Inovio Pharmaceuticals, Inc. Partners with Geneone Life Science Inc. for MERS Immunotherapy Clinical Development

Inovio Pharmaceuticals, Inc. announced it will advance its DNA vaccine for MERS (Middle East Respiratory Syndrome) into a phase I clinical trial in healthy volunteers in a collaboration with GeneOne Life Science Inc. Inovio and GeneOne will conduct a phase I trial to evaluate the safety, tolerability and immunogenicity of Inovio's DNA-based MERS vaccine. The companies are currently conducting pre-IND activities and plan to start the clinical study before year end of 2015. GeneOne will conduct and fund the clinical study in return for milestone-based co-ownership of the immunotherapy. Upon successful completion of the study, the companies plan to jointly seek additional third party support and resources to further develop and commercialize this product. In preclinical tests, INO-4500 showed robust and durable immune responses. Animals vaccinated with INO-4500 generated strong neutralizing antibodies and robust CD8+ T cells to MERS antigens. These findings are vital given the importance of neutralizing antibodies in preventing infection and the role T cells play in clearing infection by killing cells that harbor the virus. T-cell responses against multiple strains of MERS virus. Inovio's SynCon technology has the ability to activate immune responses against multiple disease-specific antigens and elicit broad protection against diverse unmatched strains of pathogens in humans. These DNA-based immunotherapy products have shown a favorable safety profile in clinical studies to date.

Inovio Pharmaceuticals Launches Clinical Testing of DNA Immunotherapy for Ebola

Inovio Pharmaceuticals (INO) announced that it has started the first phase of clinical trial evaluating its DNA immunotherapy for safety, tolerability, and immune responses in treating Ebola. In the pre-clinical testing stage, DNA-based Ebola immunotherapy protected 100% of immunized animals from death and sickness after being exposed to a lethal dose of the Ebola virus.

Inovio Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015; Provides Clinical Development Update

Inovio Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company’s total revenue was $5.166 million for the three months ended March 31, 2015, compared to $2.357 million for the same period in 2014. The increase in revenue was primarily due to payments received from Roche under its partnership agreement established in September 2013. Loss from operations was $8.367 million against $10.000 million a year ago. The net loss attributable to common stockholders for the quarter ended March 31, 2015, was $10.581 million, or $0.18 per diluted share, compared to $10.821 million, or $0.20 per diluted share, for the quarter ended March 31, 2014. The company is preparing to launch a phase III registration study of VGX-3100 in early 2016. Necessary steps include scaling up commercial-level production of its immunotherapy product and delivery devices, and completing an end-of-phase-II meeting with the FDA. As part of its expanding franchise targeting all HPV-associated precancers and cancers, the company reported preliminary data from its first cancer study, a head & neck cancer trial, showing that INO-3112 (VGX-3100 plus Inovio's IL-12 based immune activator) generated strong CD8+ T cell responses in 3 of 4 patients. The received regulatory approval to initiate a phase I study of the company’s prostate cancer DNA immunotherapy, INO-5150, targeting prostate-specific membrane antigen and prostate-specific antigen. The company intends to begin enrolling patients in the second quarter of 2015. The company initiated with its partner Roche a phase I trial for the company’s hepatitis B immunotherapy, INO-1800. This randomized, open-label, active-controlled, dose escalation study is evaluating the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy alone or in combination with Inovio's IL-12-based immune activator. With collaborators under a DARPA-funded project, the company expects to start a phase I study of its Ebola immunotherapy, INO-4212, in the second quarter of 2015. The company reported that in a 12-patient phase I study the company’s single-clade PENNVAX®-B HIV immunotherapy induced in HIV-infected patients CD8+ T cells with functional characteristics similar to those of long-term non-progressors (rare HIV-infected individuals who, without treatment, do not progress to further stages of the disease): "Synthetic consensus HIV-1 DNA induces potent cellular immune responses and synthesis of granzyme B, perforin in HIV infected individuals," Molecular Therapy. Building on these data, the company created its global, multi-clade PENNVAX®-GP preventive and therapeutic HIV DNA immunotherapy candidate with funding via a $25 million NIH contract. The company expects that the HVTN to initiate a phase I study of PENNVAX®-GP in the second quarter of 2015. The company phase I/IIa studies of INO-3112 in head & neck and cervical cancers; INO-1400 (hTERT antigen) in breast, lung or pancreatic cancer patients; and INO-8000, targeting hepatitis C virus genotypes 1a and 1b, in collaboration with GeneOne Life Sciences, Inc., are ongoing.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INO:US $8.58 USD +0.19

INO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Advaxis Inc $23.12 USD +0.65
Dynavax Technologies Corp $22.51 USD +0.15
Genocea Biosciences Inc $11.00 USD +0.01
Peregrine Pharmaceuticals Inc $1.34 USD +0.03
Vical Inc $0.96 USD +0.0326
View Industry Companies
 

Industry Analysis

INO

Industry Average

Valuation INO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 38.4x
Price/Book 4.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 39.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INOVIO PHARMACEUTICALS INC, please visit www.inovio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.